# PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor

> **NCT05803746** · NA · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** 18F-FDG

## Key facts

- **NCT ID:** NCT05803746
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-15
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05803746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05803746, "PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05803746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*